TMCnet News
The Law Offices of Frank R. Cruz Announces Investigation of NextCure, Inc. (NXTC) on Behalf of InvestorsThe Law Offices of Frank R. Cruz announces an investigation of NextCure, Inc. ("NextCure" or the "Company") (NASDAQ: NXTC) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On January 13, 2020, NextCure disclosed that Eli Lilly and Company had ended its collaboration agreement for the research and development ofthe Company's leading product candidate, NC318, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor particularly for patients with advanced or metastatic solid tumors. On this news, the Company's share price fell $4.70, or 8%, to close at $52.00 per share on January 13, 2020, thereby injuring investors. Then, on July 13, 2020, before the market opened, NextCure announced that it was no longer planning to "advance the non-small cell lung cancer (NSCLC) and ovarian cancer cohorts in the stage 2 portion of the Simon 2-stage trial." The same day, the Company announced that its Chief Medical Officer resigned. On this news, the Company's share price fell $9.73, or 54%, to close at $8.15 per share on July 13, 2020, thereby injuring investors further. Follow us for updates on Twitter (News - Alert): twitter.com/FRC_LAW. If you purchased NextCure securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922006034/en/ |
